INTRODUCTION {#s1}
============

Cancer has become a serious worldwide public health issue, and there are about 14 million new cases of cancer occurred globally, which caused about 8 million of human deaths in 2012 worldwide \[[@R1]\]. Though the surgical techniques and chemotherapy/radiotherapy regimens are with great improvement, the 5-year survival rates of the patients with certain types of cancers are still very low \[[@R1], [@R2]\]. Because of the insufficient knowledge about molecular mechanisms underlying cancer development, the overall cancer-related deaths were expected to rise in the future. Therefore, identifying novel biomarkers for early diagnosis and prognosis is necessary for us to have a better control of cancer.

The long non-coding RNAs (lncRNAs) are transcribed RNA with more than 200 nt and are incapable of coding proteins \[[@R3]\]. LncRNAs have drawn great attention in various studies because of their diverse cellular functions such cell differentiation, cell proliferation, cell apoptosis and cell survival \[[@R4], [@R5]\]. Recently, the role of lncRNAs in cancer development has been revealed in numerous studies. For example, the lncRNA, *HOX transcript antisense RNA (HOTAIR)* up-regulation serves as a novel predictive factor for poor prognosis in different types of cancers in both Asian and Western countries \[[@R6]\]. The high expression pattern and oncogenic role of the lncRNA, *colon cancer associated transcript 1 (CCAT1)* was identified in different types of cancer, and the aberrant expression of *CCAT1* is involved in several processes correlated with carcinogenesis such as cell proliferation, apoptosis, migration and invasion by regulating different target genes and pathways \[[@R7]\]. The lncRNA, *HOXA transcript at the distal tip (HOTTIP)* has been widely reported for its role in the initiation and progression of human cancers including hepatocellular carcinoma, pancreatic cancer, gastric cancer and colorectal cancer \[[@R8]\]. The lncRNA, *urothelial cancer-associated 1 (UCA1)* was identified as a common molecular marker for lymph node metastasis and prognosis in various cancers \[[@R9]\]. The lncRNA *SPRY4 intronic transcript 1*(*SPRY4-IT1*) was recently identified in melanoma, and increased expression of *SPRY4-IT1* was closely associated with tumor site and tumor stage, which indicated the prognostic role of *SPRY4-IT1* in patients with melanoma \[[@R10], [@R11]\]. In addition, the roles of *SPRY4-IT1* in cancer development were also identified in other types of cancers such as cervical cancer, colorectal cancer, lung cancer, breast cancer, liver cancer and so on, and *SPRY4-IT1* was found to be a prognostic factor in these cancers \[[@R12]--[@R16]\]. However, the underlying molecular mechanisms in cancer progression are rarely explored.

In the present study, we for the first time performed the meta-analysis to examine the association between the *SPRY4-IT1* expression level and prognosis in cancer patients. In the meta-analysis, eligible studies were included for analysis to examine the potential prognostic role of *SPRY4-IT1* in cancer patients.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

A total of 155 articles were identified by searching different databases. After excluding 75 duplicate public-ations, 80 articles were included for further screening. After carefully reviewing the title and abstract, as well as the full text, 13 studies were finally selected based on the inclusion and exclusion criteria described in the methodology section (Figure [1](#F1){ref-type="fig"}).

![Procedures of selecting eligible studies for meta-analysis](oncotarget-08-33713-g001){#F1}

Study characteristics {#s2_2}
---------------------

A total of 1329 cases from 13 included eligible studies with relevant clinical data were included in this meta-analysis. The year of publication ranges from 2014-2017. All of these studies were conducted in China, and there are 11 types of cancers among the 13 included studies. The lncRNA, *SPRY4-IT1* expression levels in these studies were all measured by quantitative real time PCR (qRT-PCR). Table [1](#T1){ref-type="table"} shows the summary of the main characteristics of the 13 included eligible studies.

###### Summary of included eligible studies for meta-analysis in the present study

  First Author          Year   Cancer type         Blood or tissue   Total number   Tumor stage           Year of survival   Adjuvant therapy before surgery   Criterion of high expression   Detection method   Outcome measures   Multivariate analysis
  --------------------- ------ ------------------- ----------------- -------------- --------------------- ------------------ --------------------------------- ------------------------------ ------------------ ------------------ -----------------------
  Cao D. \[[@R12]\]     2015   Colorectal cancer   Tissue            84             41/43 (I-II/III-IV)   3                  None                              Cut-off value                  qRT-PCR            OS                 Yes
  Cao Y. \[[@R13]\]     2016   Cervical cancer     Tissue            110            55/45 (I-II/III-IV)   5                  None                              Youden\'x index                qRT-PCR            OS                 Yes
  Li H. \[[@R33]\]      2017   Ovarian cancer      Tissue            124            48/76 (I-II/III-IV)   5                  None                              Median expression              qRT-PCR            OS, DFS            Yes
  Liu D. \[[@R34]\]     2017   Bladder cancer      Tissue            60             15/45 (I-II/III-IV)   NR                 NR                                NR                             qRT-PCR            NR                 NR
  Liu T. \[[@R11]\]     2016   Melanoma            Plasma            70             32/38 (I-II/III-IV)   5                  None                              Cut-off value                  qRT-PCR            OS                 Yes
  Peng W. \[[@R24]\]    2015   Gastric cancer      Tissue            175            95/80 (I-II/III-IV)   5                  NR                                Median expression              qRT-PCR            OS, DFS            Yes
  Shi Y. \[[@R15]\]     2015   Breast cancer       Tissue            48             23/25 (I-II/III-IV)   NR                 None                              NR                             qRT-PCR            NR                 NR
  Sun M. \[[@R16]\]     2014   NSCLC               Tissue            121            43/78 (I-II/III-IV)   3                  None                              Median expression              qRT-PCR            OS, DFS            Yes
  Tan W. \[[@R35]\]     2017   Colorectal cancer   Tissue            116            57/49 (I-II/III-IV)   5                  None                              Mean expression                qRT-PCR            OS                 Yes
  Xie H. \[[@R23]\]     2014   ESCC                Tissue            92             59/33 (I-II/III-IV)   5                  None                              Median expression              qRT-PCR            OS                 Yes
  Zhang H. \[[@R36]\]   2014   RCC                 Tissue            98             63/35 (I-II/III-IV)   5                  None                              Mean expression                qRT-PCR            OS                 Yes
  Zhao X. \[[@R22]\]    2015   Bladder cancer      Tissue            68             32/36(I-II/III-IV)    5                  None                              Mean expression                qRT-PCR            OS                 Yes
  Zhou Y. \[[@R37]\]    2016   Glioma              Tissue            163            73/90 (I-II/III-IV)   5                  NR                                Median expression              qRT-PCR            OS                 Yes

DFS = disease-free survival; ESCC = Esophageal squamous cell carcinoma; NR = not recorded; NSCLC = non-small cell lung cancer; OS = overall survival; RCC = renal cell carcinoma.

Meta-analysis of the association between *SPRY4-IT1* expression level and overall survival (OS) {#s2_3}
-----------------------------------------------------------------------------------------------

Eleven studies were included for the analysis of association between *SPRY4-IT1* expression level and OS in cancer patients. In the meta-analysis, random-effects model was applied to estimate the pooled hazard ratio (HR) and the respective 95% confident interval (CI), as heterogeneity exists among the 11 studies. As shown in Figure [2](#F2){ref-type="fig"}, the HR of the high *SPRY4-IT1* expression level group versus the low *SPRY4-IT1* expression level group was 2.45 (95% CI: 1.50-3.99) (Figure [2](#F2){ref-type="fig"}). After carefully reviewing the studies, we found that the study from Sun et al., 2014 showed a decrease of *SPRY4-IT1* in NSCLC tissues when compared to normal tissues, and down-regulation of *SPRY4-IT1* predicted shorter OS in patients with NSCLC. On the other hand, *SPRY4-IT1* was found to be up-regulated in the tissues from other studies, and up-regulation of *SPRY4-IT1* was positively correlated with shorter OS in these patients. In this regard, we excluded the study from Sun et al., 2014 \[[@R16]\], and the fixed-effects model was applied, as there was no heterogeneity in the analysis results (Figure [3](#F3){ref-type="fig"}). The HR of high *SPRY4-IT1* expression level versus the low *SPRY4-IT1* expression level group was 3.20 (95% CI: 2.59-3.95). The funnel plot analysis results showed that there was no obvious publication bias among these selected studies (Figure [4](#F4){ref-type="fig"}). Therefore, the study from Sun et al., 2014 was excluded in the following analysis.

![Forest plot of the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients from 11 studies](oncotarget-08-33713-g002){#F2}

![Forest plot of the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients from 10 studies (study for NSCLC was excluded)](oncotarget-08-33713-g003){#F3}

![Funnel plot for assessing publication bias of the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients from 10 studies (study for NSCLC was excluded)](oncotarget-08-33713-g004){#F4}

As shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}, there were nine types of cancer (bladder cancer, cervical cancer, colorectal cancer, esophageal squamous cell carcinoma (ESCC), gastric cancer, glioma, melanoma, ovarian cancer and renal cell carcinoma (RCC)) were included in the meta-analysis. We further classified these cancers into four subgroups (digestive system cancers, urinary system cancers, reproductive and other types of cancers), and the meta-analysis showed that the HR of the high *SPRY4-IT1* expression level group versus the low *SPRY4-IT1* expression level group in digest system cancers, urinary system cancer, reproductive system cancer and other types of cancer were 2.31 (95% CI: 1.59-3.36), 3.58 (95% CI: 2.19-5.83),), 5.01 (95% CI: 3.37-7.45), and 2.55 (95% CI:1.60-4.07), respectively (Table [2](#T2){ref-type="table"} and Figure [5](#F5){ref-type="fig"}), and there was no heterogeneity among studies from different subgroups (Table [2](#T2){ref-type="table"} and Figure [5](#F5){ref-type="fig"}). These results suggest that increased *SPRY4-IT1* expression level was associated with poor OS.

###### Meta-analysis results of the association between the lncRNA *SPRY4-IT1* expression level and OS in cancer patients

  Categories                    Studies (n)   Number of patients   Fixed -effects model   Heterogeneity         
  ----------------------------- ------------- -------------------- ---------------------- --------------- ----- ---------
  \[[@R1]\] OS                  10            1148                 3.20 (2.59-3.95)       \<0.001         17%   0.29
  \[[@R2]\] Cancer type                                                                                         
  1\) Digestive system          4             467                  2.31 (1.59-3.36)       \<0.001         0     0.70
  2\) Urinary system            2             166                  3.58 (2.19-5.83)       \<0.001         0     0.85
  3\) Reproductive system       2             234                  5.01 (3.37-7.45)       \<0.001         0     0.58
  4\) Others                    2             281                  2.55 (1.60-4.07)       \<0.001         0     0.76
  \[[@R3]\] Cut-off values                                                                                      
  Median                        4             554                  3.18 (2.40-4.23)       \<0.001         69    0.02
  Mean                          3             282                  3.15 (2.09-4.74)       \<0.001         0     0.63
  Others                        3             312                  3.32 (1.99-5.52)       \<0.001         0     0.93
  \[[@R4]\] Sample sizes                                                                                        
  ≥ 100                         5             688                  3.03 (1.95-4.72)       \<0.001         54    0.07
  \< 100                        5             460                  3.01 (2.17-4.19)       \<0.001         0     0.77
  \[[@R5]\] Year of survival                                                                                    
  3-year survival               1             84                   3.27 (1.55-6.89)       0.002           \-    \-
  5-year survival               9             1064                 3.27 (1.94-2.91)       \<0.001         84    \<0.001
  \[[@R6]\] Plasma vs. tissue                                                                                   
  Plasma                        1             70                   2.93 (1.10-7.81)       0.03            \-    \-
  Tissue                        9             1078                 2.41 (1.97-2.94)       \<0.001         84    \<0.001

OS = overall survival

![Forest plot of subgroup analysis (cancer type) for the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients](oncotarget-08-33713-g005){#F5}

In the further analysis, we also divided these studies into subgroups based on definition of cut-off values for *SPRY4-IT1* expression level, sample size of each study, 3 or 5 year overall survival, and plasma *SPRY4-IT1* versus tissue *SPRY4-IT1*, and we obtained similar results, in which the increased expression level was associated with poor overall survival in different subgroups divided based on above criteria (Table [2](#T2){ref-type="table"} and see forest plot of the analysis in Figure [6](#F6){ref-type="fig"}, Figure [7](#F7){ref-type="fig"}, [Supplementary Figure 2 and 3](#SD1){ref-type="supplementary-material"}).

![Forest plot of subgroup analysis (cut-off values) for the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients](oncotarget-08-33713-g006){#F6}

![Forest plot of subgroup analysis (sample size) for the association between lncRNA *SPRY4-IT1* expression level and overall survival in cancer patients](oncotarget-08-33713-g007){#F7}

Sensitivity analysis {#s2_4}
--------------------

For the meta-analysis of the association between *SPRY4-IT1* expression level and OS, the sensitivity analysis was performed by removing each study in turn from the pooled analysis. This analysis aims to evaluate the impact of the removed study on the pooled HRs. In the present study, removing any of the included studies had no significant impact on the meta-analysis outcomes, which suggests the robustness of the results.

Meta-analysis of the association between *SPRY4-IT1* expression level and disease-free survival (DFS) {#s2_5}
-----------------------------------------------------------------------------------------------------

A total of 2 studies were included in the meta-analysis, and there are gastric cancer and ovarian cancer. The meta-analysis results showed that the HR of association between increased *SPRY4-IT1* expression level and DFS in these cancer patients was 3.03 (95% CI: 2.51-3.65), and I^2^= 97% and P~h~\<0.001, suggesting that there is great heterogeneity existing between these studies (Figure [8](#F8){ref-type="fig"}). More data may be collected in the future to confirm the association between *SPRY4-IT1* expression level and DFS in cancer patients

![Forest plot of the association between lncRNA *SPRY4-IT1* expression level and disease-free survival in cancer patients](oncotarget-08-33713-g008){#F8}

Meta-analysis of the association between *SPRY4-IT1* expression and clinical pathological parameters {#s2_6}
----------------------------------------------------------------------------------------------------

We pooled all the clinicopathological data from these eligible studies to do further meta-analysis for the association between *SPRY4-IT1* expression level and clinicopathological characteristics. As shown in Table [3](#T3){ref-type="table"}, the meta-analysis results showed that the *SPRY4-IT1* expression level was not correlated with the clinicopathological parameters including age (P = 0.37, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}), gender (P = 0.87, [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}), tumor size (P = 0.47, [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}) and invasion depth (P = 0.52, [Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). However, the meta-analysis showed that the increased *SPRY4-IT1* expression level was significantly associated with distant metastasis (odds ratio (OR) = 1.96, 95% CI: 1.24-3.08, P = 0.004, [Supplementary Figure 8](#SD1){ref-type="supplementary-material"}), lymph node metastasis (OR = 3.96, 95% CI: 1.48-5.54, P\<0.001, [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}), advanced tumor/node/metastasis (TNM) stage (OR = 3.72, 95% CI = 2.91-4.76, P\<0.001, [Supplementary Figure 10](#SD1){ref-type="supplementary-material"}), and poor tumor differentiation (OR = 1.86, 95% CI = 1.35-2.58, P\<0.001, [Supplementary Figure 11](#SD1){ref-type="supplementary-material"}). Because of the insufficient data for other clinicopathological parameters (such as tumor location, family history of cancer, alcohol consumption), the relationship between increased *SPRY4-IT1* expression level and these clinicopathological parameters were not processed for the meta-analysis.

###### Meta-analysis results for the association between the lncRNA *SPRY4-IT1* expression level and clinico-pathological parameters

  Clinicopathological parameters                   Studies (n)   Patients (n)   OR (95% CI)         *P*-value   Heterogeneity             
  ------------------------------------------------ ------------- -------------- ------------------- ----------- --------------- --------- --------
  Age (≥ 55 vs. \< 55 years)                       12            1173           0.90 (0.70-1.14)    0.37        18              0.26      Fixed
  Gender (Male vs. Female)                         10            1067           0.98 (0.76-1.25)    0.87        0.51            0         Fixed
  Tumor size (≥ 5 cm vs. \<5 cm)                   5             574            1.36 (0.59-3.15)    0.47        81              \<0.001   Random
  Invasion depth (T~3~-T~4~ vs. T~1~-T~2~)         3             341            1.85 (0.29-11.98)   0.52        90              \<0.001   Random
  Distant metastasis (Yes vs. No)                  5             409            1.96 (1.24-3.08)    0.004       48              0.1       Fixed
  Lymph node metastasis (Yes vs. No)               9             780            3.96 (1.48-5.54)    \<0.001     18              0.28      Fixed
  TNM stage (III-IV vs. I-II)                      12            1065           3.72 (2.91- 4.76)   \<0.001     23              0.22      Fixed
  Tumor differentiation (Poor vs. Moderate/Well)   7             689            1.86 (1.35-2.58)    \<0.001     35              0.16      Fixed

DISCUSSION {#s3}
==========

The lncRNAs *SPRY4-IT1* is derived from an intron of the Sprouty 4 (*SPRY4*) gene \[[@R10]\]. *SPRY4-IT1* is located in the cytoplasm and is predicted to have several long hairpins in its secondary structure. Studies have suggested that *SPRY4-IT1* may act as molecular scaffolds for protein complexes that lack protein-protein interaction domains or can interact directly with microRNAs and prevent them from binding to mRNA, thus regulating protein synthesis \[[@R10]\]. In the aspect of cancer studies, *SPRY4-IT1* dysregulation was found to be closely associated with tumor development and also contributed to cell proliferation, cell apoptosis and cell invasion and cell migration in different types of cancers \[[@R10], [@R12]--[@R14], [@R17]\]. These findings may suggest the critical function of *SPRY4-IT1* in cancer progression and *SPRY4-IT1* may serve as a novel biomarker for early diagnosis and prognosis in cancer patients.

Several studies have elucidated the molecular mechanisms underlying *SPRY4-IT1* involved tumor development. SPRY4-TI1 was found to promote cell proliferation, migration and invasion via regulating epithelial--mesenchymal transition in various types of cancers including gastric cancer, colorectal cancer, ESCC, glioma and NSCLC \[[@R12], [@R16]--[@R19]\]. In addition, *SPRY4-IT1* also demonstrated the oncogenic role via targeting zinc finger protein 703 in breast cancer and ESCC \[[@R15], [@R20]\]. In the osteosarcoma, *SPRY4-IT1* can promote epithelial mesenchymal transition via interaction with *Snail* \[[@R21]\]. More importantly, the knock-down of *SPRY4-IT1* inhibited cell growth and cell differentiation, also induced apoptosis in melanoma \[[@R10]\]. In the aspect of the prognostic role of *SPRY4-IT1*, the increased expression of *SPRY4-IT1* was closely associated with poor prognosis in various types of cancers including bladder cancer, cervical cancer, colorectal cancer, ESCC, gastric cancer, glioma, melanoma, NSCLC and RCC \[[@R6], [@R11]--[@R13], [@R16], [@R18], [@R22]--[@R25]\]. Thus, the collective evidence may imply the oncogenic role of *SPRY4-IT1* in different types of cancers and targeting *SPRY4-IT1* may be beneficial for the treatment of human cancers.

In the present study, the meta-analysis results showed that increased *SPRY4-IT1* expression level was significantly associated with shorter OS, which suggests the prognostic role of *SPRY4-IT1* in predicting OS in cancer patients. Consistently, other lncRNAs such as *HOTAIR*, *H19* and *UCA1* were also found to predict the shorter OS in cancer patients \[[@R9], [@R26], [@R27]\]. In the future study, analysis of more than one lncRNAs may represent a better solution for predicting OS in cancer patients. Apart from the examining the role *SPRY4-IT1* in predicting OS, we also found that increased *SPRY4-IT1* expression level was also significantly correlated with shorter DFS in cancer patients. Similarly, the increased expression of the lncRNA *UCA1* also predicted the shorter DFS in patients with gastric cancer or HCC \[[@R28]\]. In addition, elevated lncRNA, *metastasis associated lung adenocarcinoma transcript 1* expression was also a significant predictor for DFS in patients with digestive system cancers \[[@R29]\]. For the lncRNA *HOTAIR*, its up-regulation also predicted the shorter DFS in cancer patients \[[@R30]\]. Therefore, these results may suggest that increased *SPRY4-IT1* expression level may predict the poor prognosis in various cancers.

Several lines of studies also showed the correlation between lncRNAs and clinicopathological parameters. Here, we showed that increased *SPRY4-IT1* expression was significantly associated with distant metastasis, lymph node metastasis, advanced TNM stage, and poor tumor differentiation. Indeed, *UCA1, PVT1 and H19* can serve as a molecular marker for lymph node metastasis in various cancers \[[@R9], [@R27], [@R31]\]. Liu et al., also found that the lncRNA, *low expression in tumor* was associated with lymph node metastasis and distant metastasis in human cancers \[[@R32]\]. All in all, our results may suggest that increased *SPRY4-IT1* may be associated with advanced features of cancer.

In the present study, there are still several limitations in the meta-analysis. For example, the total sample size was relatively small, and the patients included in the meta-analysis were all from one country. In addition, the cut-off definition for high *SPRY4-IT1* expression was not consistent among the included studies. Finally, publication bias may exist, despite the fact that no obvious publication bias was observed based on stable results revealed in sensitivity analysis as well as funnel plot analysis. All in all, larger-size, multi-center and higher-quality studies with unified criteria for defining *SPRY4-IT1* expression are essential to solidify the findings in this study. In the present study, only one study from Sun et al., 2014 \[[@R16]\] showed a decrease of *SPRY4-IT1* in cancer tissues and decreased expression of *SPRY4-IT1* was associated with poor clinical outcomes, which was contrast with other included studies. In addition, one study from Xie et al., 2015 \[[@R18]\] also showed a decrease of *SPRY4-IT1* in gastric cancer, which was not consistent with the study from Peng et al., 2015 \[[@R24]\], and after carefully reviewing the data from Xie et al., 2015 \[[@R18]\], we found that the description of results was not consistent with the figures (in Figure [1A](#F1){ref-type="fig"} from Xie et al., SPRY4-IT1 was up-regulated in gastric cancer tissue, while in the results section, the SPRY4-IT1 was described to be down-regulated in gastric cancer tissue), and this study was not included in the current meta-analysis.

In summary, the meta-analysis results suggest the prognostic role of *SPRY4-IT1* in human cancers, and increased *SPRY4-IT1* expression was closely associated with advanced features of human cancers except NSCLC. However, due to several limitations of the included studies, more high-quality studies may be required to further confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Comprehensive literature search was performed in the following databases: Pubmed, EMBASE, CNKI, Web of Science and Google Scholar to retrieve potential eligible studies for meta-analysis and the cut-off date was defined as Feb, 2017. The keywords for the search in these databases included: "*SPRY4-IT1*", " *SPRY4 Intronic Transcript 1*", "long non-coding RNA *SPRY4-IT1*", "lncRNA *SPRY4-IT1*", "cancer", "tumor", "carcinoma", "neoplasm", and other eligible studies were also manually retrieved from the relevant reference lists.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria for the eligible studies included: (a) associations of *SPRY4-IT1* expression levels with OS, DFS or clinicopathological features were described, (b) the role of *SPRY4-IT1* in human cancer development was examined, (c) patients were categorized into two groups based on high and low expression levels of *SPRY4-IT1*, (d) the expression levels of *SPRY4-IT1* in the cancer patients were determined by qRT-PCR. Exclusion criteria for the articles included: (a) studies without presenting data with relevant values, (b) duplicated publications, (c) letters, reviews, case reports and expert opinions.

Data extraction and quality assessment {#s4_3}
--------------------------------------

The data and information from all included eligible studies were independently assessed by two investigators (H.S. and N.S.). The following information were extracted from each eligible study: the name of first author, year of publication, cancer type, total number of patients from each eligible study, TNM stage, year of survival examined, criteria for defining high expression level of *SPRY4-IT1* and low expression level of *SPRY4-IT1*, method for detecting *SPRY4-IT1* expression, outcome measures, HR and its corresponding 95% CI, the clinicopathological parameters from each eligible study. In the eligible studies only reporting Kaplan-Meier curves, the software, Enguage Digitizer (Version 4.1) was used to extract the survival data. For the eligible studies that provided both the univariate and multivariate analysis, the multivariate values were chosen as the multivariate values had higher precision on interpreting confounding factors. In the situation of a disagreement, a consensus was reached by a third investigator (T.L.). The quality of all the included studies were assessed by The Newcastle-Ottawa Scale (NOS) method. The NOS scores ranged from 0 to 9, and a study with an NOS score more than 6 was regarded as high quality.

Statistical analysis {#s4_4}
--------------------

The meta-analysis was performed with Stata SE12.0 and RevMan 5.3 software. The heterogeneity between studies was determined by the Chi square-based Q test and I^2^ statistics. *P*\<0.05 for the Q test (P~h~) and I^2^\>50% were considered to be significantly heterogeneous. The fixed effects model was applied in the studies with no obvious heterogeneity (P~h~\>0.05, I^2^\<50%); the random effects model was applied in the studies with obvious heterogeneity (P~h~≤0.05, I^2^≥50%). The sensitivity analysis was also carried out to assess the stability of the results. A *P* values less than 0.05 was considered to be statistically significant.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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